RedHill Biopharma Ltd. (RDHL)

3.20
0.20 6.70
NASDAQ : Health Technology
Prev Close 3.00
Open 3.11
Day Low/High 2.70 / 3.15
52 Wk Low/High 2.57 / 11.52
Volume 1.34M
Avg Volume 448.40K
Exchange NASDAQ
Shares Outstanding 35.27M
Market Cap 247.59M
EPS -1.40
P/E Ratio 69.45
Div & Yield N.A. (N.A)
Dismiss the Impact of Rising Inflation and COVID Cases at Your Own Risk

Dismiss the Impact of Rising Inflation and COVID Cases at Your Own Risk

The overall market seems to be mispricing the threats of rapidly increasing prices and the fast-spreading Delta variant.

Hopping on a Couple Compelling Opportunities in a Market That Isn't

Hopping on a Couple Compelling Opportunities in a Market That Isn't

Dips in the shares of Redhill Biopharma and FibroGen Inc. provided the chance for the author to employ his covered call strategy.

Veeva and RedHill: 2 Stocks to Consider as They Team Up to Battle Covid-19

Veeva and RedHill: 2 Stocks to Consider as They Team Up to Battle Covid-19

RedHill Biopharma has adopted 'Veeva Vault CDMS', Veeva's modern cloud platform.

Let's Head Overseas for a Trio of Undervalued Healthcare Plays

Let's Head Overseas for a Trio of Undervalued Healthcare Plays

These promising companies look like good names for patient buy-and-hold investors.

2 Picks, 2 Pans Among Small-Cap Biotechs Laboring in the Covid-19 Fields

2 Picks, 2 Pans Among Small-Cap Biotechs Laboring in the Covid-19 Fields

Quotient Limited and Redhill Biopharma could deliver for shareholders, while Novavax Inc. and Inovio Pharmaceuticals may not in the end.

3 Small-Caps That Look Like Bargains at Current Trading Levels

3 Small-Caps That Look Like Bargains at Current Trading Levels

The trio consists of BioDelivery Sciences International, Beazer Homes USA and Redhill Biopharma.

2 Key 'Rules' When Investing in Biotech Stocks

2 Key 'Rules' When Investing in Biotech Stocks

Remembering these 'rules of the road' is vital in this highly volatile space.

How I Invest In Biotech Stocks

How I Invest In Biotech Stocks

Here's two 'rules of the road' when investing in this highly volatile space.

Celgene Down After Pulling Plug on Crohn's Disease Drug Study -- Biotech Movers

Celgene Down After Pulling Plug on Crohn's Disease Drug Study -- Biotech Movers

The Summit, N.J.-based firm said Thursday that it was discontinuing the GED-0301 (mongersen) Phase 3 Revolve study in Crohn's disease and the extension trial.

3 Small Biotechs That Still Have Upside

3 Small Biotechs That Still Have Upside

Companies developing drugs for cancer, eye problems and pets -- offer untapped value.

One Small Pharma Stock Has Big Potential

One Small Pharma Stock Has Big Potential

Redhill has some promising drugs in its pipeline, and is well funded.

5 Small-Cap Biotechs With Big Potential

5 Small-Cap Biotechs With Big Potential

These 5 stocks all have positive catalysts on the horizon.

5 Small-Cap Biotechs With Big Potential

5 Small-Cap Biotechs With Big Potential

These 5 stocks all have positive catalysts on the horizon.